BioSpace News Archive

Company Created ACCEL (Access to Excellent Care for Sickle Cell Patients Pilot Program) to Accelerate Development of Innovative Healthcare Programs for Sickle Cell Community

Alpha Genesis, a primate research organization, was recognized by the Beaufort Chamber of Commerce for its significant regional economic impact during its 2019 Civitas Awards for Business Excellence, held on Dataw Island the evening of June 7.

Approval Triggers Milestone Payment and Royalties on Worldwide Net Sales

HealthChampion (www.myhealthchampion.com) -- the world’s first platform giving people unprecedented control over their healthcare information to improve their individual health goals and outcomes -- is now fully HIPAA compliant.

On Saturday June 8, 2019 in Winnipeg, Maxim Truck & Trailer had a team of 68 walkers and volunteers who raised $230,024 for CancerCare Manitoba’s 2019 Challenge for Life event.

In an analysis of the AWARD-7 study, people with type 2 diabetes (T2D) and moderate-to-severe chronic kidney disease (CKD) who took 1.5 mg of dulaglutide once weekly had a reduction of clinical events associated with end-stage kidney disease (ESKD) including dialysis and with a kidney transplant, and a slower rate of kidney function decline compared to people who used insulin or a lower dose of dulaglutide.

Frelii Inc. announced the details of its recent agreement with Orn Health Inc. to license the Frelii exome and whole genome sequencing and artificial intelligence (AI) technology for use with new franchisee partners in their own medical practices for enhancing patient treatment resources.

Evofem Biosciences, Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical company, and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today announced the closing of the second tranche for $50 million of an aggregate $80 million strategic financing from PDL and existing Evofem investors, Invesco Asset Management, LTD. (Invesco) and Woodford Investment Management (WIM).

Valens GroWorks Corp. is pleased to announce that it has expanded the volume of extraction services and has added an option to provide contract manufacturing services to the arm’s length, binding multi-year agreement previously announced February 26, 2019 with Tilray Inc., a global leader in cannabis research, cultivation, production and distribution.

Resolve Therapeutics, an immuno-therapeutics company developing first-in-class, safe, targeted therapies for underserved autoimmune diseases, today announced that an oral presentation on the Company’s lead product candidate, RSLV-132, will be presented at the 2019 European League Against Rheumatism (EULAR) European Congress of Rheumatology in Madrid, Spain.